---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-014303"
form_type: "8-K"
ticker: "CVRX"
cik: "0001235912"
company_name: "CVRx, Inc."
filed_at: "2026-02-12T23:59:59+00:00"
generated_at: "2026-05-16T02:55:56.816617+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CVRx Q4 2025 revenue $16.0M (+4% YoY); net loss $11.9M; FY2026 rev guidance $63-67M

## Summary
- Q4 revenue $16.0M (US $14.9M, Europe $1.1M); gross margin 86% vs 83% YoY.
- Net loss $11.9M ($0.46/sh) vs $10.7M ($0.43/sh) in Q4 2024; full year net loss $53.3M ($2.04/sh).
- Active US implanting centers 252 (up 29 YoY); 53 US sales territories; BENEFIT-HF trial enrollment expected Q2 2026.
- Jan 2026 amended debt facility: added $10M borrowing to $60M total, interest-only period extended, maturity May 2031.
- FY2026 guidance: revenue $63-67M, gross margin 84-86%, op. expenses $103-107M; Q1 2026 revenue expected $13.7-14.7M.

## SEC filing metadata
- accession: 0001104659-26-014303
- form_type: 8-K
- ticker: CVRX
- cik: 0001235912
- company_name: CVRx, Inc.
- filed_at: 2026-02-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1235912/000110465926014303/0001104659-26-014303-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1235912/000110465926014303/tm266143d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-014303
- JSON: https://secwatch.observer/filing/0001104659-26-014303.json
- Plain text: https://secwatch.observer/filing/0001104659-26-014303.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.